BLOOD LIPIDS IN CHRONIC PANCREATITIS COMBINED WITH CORONARY HEART DISEASE: LIMITATIONS OF CORRECTION
He pathogenesis of comorbidity of these disorders and in the dynamics during treatment with policosanol. Materials and Methods. The study was carried out in 22 patients (including 10 patients with chronic pancreatitis and dyslipidemia and 12 patients with comorbidity of chronic pancreatitis and coronary heart disease in chronic heart failure syndrome of I-II A-B stage II-III functional class) and in 10 apparently healthy volunteers. There we 13 men, 9 women aged from 31 to 69 years. Two groups of patients, in addition to the treatment protocol, were administered 10 mg of policosanol once daily during dinner, for up to 3 months. To study the blood lipids features there was determined the level of total cholesterol, high density lipoprotein cholesterol, triglycerides (using reagents of Lachema company (Czech Republic) by Zlatkis - Zak method). Level of low density lipoprotein cholesterol was determined using the calculation method by Friedewald equation considering that the concentration of triglycerides did not exceed 4.5 mmol/l. In addition, very low density lipoprotein cholesterol and atherogenic index were measured using conventional calculation methods. Results. In patients with chronic pancreatitis associated with coronary heart disease, in the majority of cases there is a significant (p < 0.05) increase in parameters of total cholesterol, low and very low density lipoproteins, triglycerides. When analyzing the types of dyslipidemia, it was found that the more common types were IIa and IIb (22 and 25 %, respectively), but in comorbidity, IIa and ІV types of dyslipidemia were detected more often. In the dynamics of three- month treatment with policosanol, in patients with chronic pancre- atitis the parameters of high density lipoprotein cholesterol increased and indices of triglycerides decreased, indicating lipid-lowering ef- fect of the drug and the possibility of using it in combination with statins to achieve a reduction in risk of cardiovascular events. Conclusion. Comorbidity of chronic pancreatitis with coronary heart disease increases the risk of dyslipidemia and atherosclerosis progression. Proof of this is the increased atherogenic index in this group of patients, along with the severity of blood lipids disorders. Additional to the course of treatment administration of policosanol to patients with chronic pancreatitis and dyslipidemia, as well as in combination with coronary heart disease promotes decrease and normalization of some parameters of blood lipids. This allows you to recommend the drug for long-term treatment of these groups of patients, including in conjunction with statin therapy.